Patents by Inventor Jeffrey Alan Dodge

Jeffrey Alan Dodge has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Selective estrogen receptor modulator for the treatment of osteoarthritis
    Patent number: 8476300
    Abstract: The present invention is directed to a compound of the formula (A): or a pharmaceutically acceptable salt thereof; and also to compounds of formula (I): or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 3, 2009
    Date of Patent: July 2, 2013
    Assignee: Eli Lilly and Company
    Inventors: Jeffrey Alan Dodge, Timothy Ivo Richardson, Christian Alexander Clarke, Scott Alan Jones, Ronald Jay Hinklin, Conrad Wilson Hummel, George Sal Lewis
  • Selective estrogen receptor modulators for the treatment of vasomotor symptoms
    Patent number: 8217032
    Abstract: The present invention relates to a selective estrogen receptor modulator of formula I or Ia: (I) (Ia); or a pharmaceutical acid addition salt thereof; useful for treating vasomotor symptoms, in particular hot flashes, night sweats and other symptoms that affect women around menopause.
    Type: Grant
    Filed: June 23, 2011
    Date of Patent: July 10, 2012
    Assignee: Eli Lilly and Company
    Inventors: Robert Dean Dally, Jeffrey Alan Dodge, Scott Alan Frank, Ronald Jay Hinklin, Timothy Alan Shepherd, Owen Brendan Wallace
  • SELECTIVE ESTROGEN RECEPTOR MODULATORS FOR THE TREATMENT OF VASOMOTOR SYMPTOMS
    Publication number: 20110281847
    Abstract: The present invention relates to a selective estrogen receptor modulator of formula I or Ia: (I) (Ia); or a pharmaceutical acid addition salt thereof; useful for treating vasomotor symptoms, in particular hot flashes, night sweats and other symptoms that affect women around menopause.
    Type: Application
    Filed: June 23, 2011
    Publication date: November 17, 2011
    Applicant: ELI LILLY AND COMPANY
    Inventors: Robert Dean Dally, Jeffrey Alan Dodge, Scott Alan Frank, Ronald Jay Hinklin, Timothy Alan Shepherd, Owen Brendan Wallace
  • Selective Estrogen Receptor Modulator for the Treatment of Osteoarthritis
    Publication number: 20110166182
    Abstract: The present invention is directed to a compound of the formula (A): or a pharmaceutically acceptable salt thereof; and also to compounds of formula (I): or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 3, 2009
    Publication date: July 7, 2011
    Applicant: ELI LILLY AND COMPANY
    Inventors: Jeffrey Alan Dodge, Timothy Ivo Richardson, Christian Alexander Clarke, Scott Alan Jones, Ronald Jay Hinklin, Conrad Wilson Hummel, George Sal Lewis
  • Selective estrogen receptor modulators containing a phenylsulfonyl group
    Patent number: 7585977
    Abstract: The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.
    Type: Grant
    Filed: April 9, 2008
    Date of Patent: September 8, 2009
    Assignee: Eli Lilly and Company
    Inventors: Robert Dean Dally, Jeffrey Alan Dodge, Scott Alan Frank, Scott Alan Jones, Timothy Alan Shepherd, Owen Brendan Wallace, Kin Chlu Fong, Conrad Wilson Hummel, George Sal Lewis
  • Indole Sulfonamide Modulators of Progesterone Receptors
    Publication number: 20090069400
    Abstract: Compounds of Formula (I), wherein n is 1 or 2, and R1, R2, R3, R4, R5, R6, R7, and R8 are as defined herein, their preparation, pharmaceutical compositions, and methods of use are disclosed.
    Type: Application
    Filed: January 17, 2007
    Publication date: March 12, 2009
    Inventors: Thomas John Bleisch, Christian Alexander Clarke, Jeffrey Alan Dodge, Scott Alan Jones, Jose Eduardo Lopez, Charles Willis Lugar, III, Brian Stephen Muehl, Timothy Ivo Richardson, Ying Kwong Yee, Kuo-Long Yu
  • Selective Estrogen Receptor Modulators for the Treatment of Vasomotor Symptoms
    Publication number: 20090023917
    Abstract: The present invention relates to a selective estrogen receptor modulator of formula I or Ia: (I) (Ia); or a pharmaceutical acid addition salt thereof; useful for treating vasomotor symptoms, in particular hot flashes, night sweats and other symptoms that affect women around menopause.
    Type: Application
    Filed: January 18, 2005
    Publication date: January 22, 2009
    Applicant: Eli Lilly and Company
    Inventors: Robert Dean Dally, Jeffrey Alan Dodge, Scott Alan Frank, Ronald Jay Hinklin, Timothy Alan Shepherd, Owen Brendan Wallace
  • Pentalfluoroalkanesulfinyl naphthalenes and related estrogen receptor modulators
    Patent number: 7462647
    Abstract: The present invention provides a compound of the formula (I) wherein R is —H, or —C1-C4 alkyl; R1 is —H, —OH, —O(C1-C4 alkyl), —SO2(C1-C4 alkyl), or halo; X is —O—, —CH2—, or —C(O)—; X1 is —O— or —NR2—; R2 is —H or —CH3; Y is —S—, —CH2CH2—, or —HC?CH—; m is 0, 1, 2, or 3; and n is 0 or 1; or a pharmaceutically acceptable salt thereof; pharmaceutical compositions thereof; and methods for inhibiting a disease associated with an aberrant physiological response to endogenous estrogen.
    Type: Grant
    Filed: May 27, 2004
    Date of Patent: December 9, 2008
    Assignee: Eli Lilly and Company
    Inventors: Jeffrey Alan Dodge, Norman Earle Hughes
  • Selective Estrogen Receptor Modulators
    Publication number: 20080227814
    Abstract: The present invention relates to a selective estrogen receptor modulator selected from the group consisting of: (I) or a pharmaceutical salt thereof; useful, e.g., for treating endometriosis and uterine leiomyoma.
    Type: Application
    Filed: January 18, 2005
    Publication date: September 18, 2008
    Inventors: Jeffrey Alan Dodge, Scott Alan Frank, Ronald Jay Hinklin, Owen Brendan Wallace
  • Selective Estrogen Receptor Modulators
    Publication number: 20080221163
    Abstract: The present invention relates to a selective estrogen receptor modulator of formula I: I; or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and uterine leiomyoma.
    Type: Application
    Filed: January 18, 2005
    Publication date: September 11, 2008
    Inventors: Jeffrey Alan Dodge, Randall Bruce Hopkins, Owen Brendan Wallace
  • SELECTIVE ESTROGEN RECEPTOR MODULATORS CONTAINING A PHENYLSULFONYL GROUP
    Publication number: 20080214612
    Abstract: The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.
    Type: Application
    Filed: April 9, 2008
    Publication date: September 4, 2008
    Inventors: Robert Dean Dally, Jeffrey Alan Dodge, Scott Alan Frank, Scott Alan Jones, Timothy Alan Shepherd, Owen Brendan Wallace, Kin Chlu Fong, Conrad Wilson Hummel, George Sal Lewis
  • Substituted benzopyrans as selective estrogen receptor-beta agonists
    Patent number: 7217734
    Abstract: The present invention relates to substituted benzopyran derivatives, stereoisomers, and pharmaceutical acceptable salts thereof and processes for the preparation of the same. The compounds of the present invention are useful as Estrogen Receptor ? agonists. Such agonists are useful for the treating Estrogen Receptor ? mediated diseases such as prostate cancer.
    Type: Grant
    Filed: November 7, 2002
    Date of Patent: May 15, 2007
    Assignee: Eli Lilly and Company
    Inventors: Jeffrey Alan Dodge, Venkatesh Krishnan, Charles Willis Lugar, III, Blake Lee Neubauer, Bryan Hurst Norman, Lance Allen Pfeifer, Timothy Ivo Richardson
  • Substituted dipeptides as growth hormone secretagogues
    Patent number: 7125840
    Abstract: This invention relates to novel compounds which are useful in the modulation of endogenous growth hormone levels in a mammal. The invention further relates to novel intermediates for use in the synthesis of said compounds, as well as novel processes employed in these syntheses. Also included are methods of treating a mammal which include the administration of said compounds.
    Type: Grant
    Filed: October 9, 2001
    Date of Patent: October 24, 2006
    Assignee: Eli Lilly and Company
    Inventors: Jeffrey Alan Dodge, Britta Evers, Louis Nickolaus Jungheim, Brian Stephen Muehl, Gerd Ruehter, Kenneth Jeff Thrasher
  • Growth hormone secretagogues
    Patent number: 6992097
    Abstract: This invention relates to novel compounds which are useful in the modulation of endogenous growth hormone levels in a mammal. The invention further relates to novel intermediates for use in the synthesis of said compounds, as well as novel processes employed in these syntheses. Also included are methods of treating a mammal which include the administration of said compounds.
    Type: Grant
    Filed: June 3, 2003
    Date of Patent: January 31, 2006
    Assignee: Eli Lilly and Company
    Inventors: Kenneth Lee Hauser, Jeffrey Alan Dodge, Mark Louis Heiman, Scott Alan Jones, Charles Arthur Alt, Henry Uhlman Bryant, Jeffrey Daniel Cohen, James Densmore Copp, Kennan Joseph Fahey, William Harlan Gritton, Louis Nickolaus Jungheim, Joseph Henry Kennedy, Charles Willis Lugar, III, Brian Stephen Muehl, Alan David Palkowitz, Andrew Michael Ratz, Gary Anthony Rhodes, Roger Lewis Robey, David Edward Seyler, Timothy Alan Shepherd, Kenneth Jeff Thrasher, William George Trankle
  • Substituted benzopyrans as selective estrogen receptor-beta agonists
    Publication number: 20040249167
    Abstract: The present invention relates to substituted benzopyran derivatives, stereoisomers, and pharmaceutical acceptable salts thereof and processes for the preparation of the same. The compounds of the present invention are useful as Estrogen Receptor &bgr; agonists. Such agonists are useful for the treating Estrogen Receptor &bgr; mediated diseases such as prostate cancer.
    Type: Application
    Filed: April 20, 2004
    Publication date: December 9, 2004
    Inventors: Jeffrey Alan Dodge, Venkatesh Krishnan, Charles Willis Lugar, Blake Lee Neubauer, Bryan Hurst Norman, Lance Allen Pfeifer, Timothy Ivo Richardson
  • Growth hormone secretagogues
    Patent number: 6828331
    Abstract: What is disclosed are growth hormone secretagogues, and their uses, of the formula wherein R1 is C6H5CH2OCH2—, C6H5 (CH2)3— or indol-3-ylmethyl; Y is pyrrolidin-1-yl, 4-C1-C6 alkylpiperidin-1-yl or NR2R2; R2 are each independently a C1 to C6 alkyl; R3 is 2-napthyl or phenyl para-substituted by W; W is H, F, CF3, C1-C6 alkoxy or phenyl; and R4 is H or CH3, or a pharmaceutically acceptable salt or solvate thereof.
    Type: Grant
    Filed: July 25, 2001
    Date of Patent: December 7, 2004
    Assignee: Eli Lilly and Company
    Inventors: Jeffrey Alan Dodge, Charles Willis Lugar, III
  • Growth Hormone secretagogues
    Publication number: 20040122234
    Abstract: This invention relates to novel compounds which are useful in the modulation of endogenous growth hormone levels in a mammal. The invention further relates to novel intermediates for use in the synthesis of said compounds, as well as novel processes employed in these syntheses. Also included are methods of treating a mammal which include the administration of said compounds.
    Type: Application
    Filed: June 3, 2003
    Publication date: June 24, 2004
    Inventors: Kenneth Lee Hauser, Jeffrey Alan Dodge, Mark Louis Heiman, Scott Alan Jones, Charles Arthur Alt, Henry Uhlman Bryant, Jeffrey Daniel Cohen, James Densmore Copp, Kennan Joseph Fahey, William Harlan Gritton, Louis Nickolaus Jungheim, Joseph Henry Kennedy, Charles Willis Lugar, Brian Stephen Muehl, Alan David Palkowitz, Andrew Michael Ratz, Gary Anthony Rhodes, Roger Lewis Robey, David Edward Seyler, Timothy Alan Shepherd, Kenneth Jeff Thrasher, William George Trankle
  • Substituted dipeptides as growth hormone secretagogues
    Publication number: 20040058971
    Abstract: This invention relates to novel compounds which are useful in the modulation of endogenous growth hormone levels in a mammal. The invention further relates to novel intermediates for usein the synthesis of said compounds, as well as novel processes employed in these syntheses. Also included are methods of treating a mammal which include the administration of said compounds.
    Type: Application
    Filed: March 14, 2003
    Publication date: March 25, 2004
    Inventors: Jeffrey Alan Dodge, Britta Evers, Louis Nickolaus Jungheim, Brian Stephen Muehl, Gerd Ruehter, Kenneth Jeff Thrasher
  • Growth hormone secretagogues
    Patent number: 6639076
    Abstract: This invention relates to novel compounds of formula I wherein A, B, D, E, G, J, L, X, V are as defined in the specification, and the compounds are useful in the modulation of endogenous growth hormone levels in a mammal.
    Type: Grant
    Filed: April 17, 2001
    Date of Patent: October 28, 2003
    Assignee: Eli Lilly and Company
    Inventors: Kenneth Lee Hauser, Jeffrey Alan Dodge, Mark Louis Heiman, Scott Alan Jones, Charles Arthur Alt, Henry Uhlman Bryant, James Densmore Copp, William Harlan Gritton, Charles Willis Lugar, III, Brian Stephen Muehl, Alan David Palkowitz, Andrew Michael Ratz, Gary Anthony Rhodes, Roger Lewis Robey, Timothy Alan Shepherd, Kenneth Jeff Thrasher, William George Trankle
  • Substituted benzopyrans as selective estrogen receptor &bgr; agonists
    Patent number: 6630508
    Abstract: The present invention relates to substituted benzopyran derivatives, stereoisomers, and pharmaceutical acceptable salts thereof and processes for the preparation of the same. The compounds of the present invention are useful as Estrogen Receptor &bgr; agonists. Such agonists are useful for treating Estrogen Receptor &bgr; mediated diseases such as prostate cancer.
    Type: Grant
    Filed: January 22, 2003
    Date of Patent: October 7, 2003
    Assignee: Eli Lilly and Company
    Inventors: Jeffrey Alan Dodge, Venkatesh Krishnan, Charles Willis Lugar, III, Blake Lee Neubauer